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Abstract 
Patients with hereditary retinoblastoma 
are at increased risk for second 
malignancies, most notably sarcomas, 
particularly after treatment with 
radiation. Malignant phyllodes tumor is 
a rare secondary malignancy in these 
patients. We present a review of the 
literature and report of a patient with 
hereditary retinoblastoma who 
developed two secondary malignancies, 
including malignant phyllodes tumor.  
The patient’s phyllodes tumor presented 
as a palpable breast mass with 
suspicious findings on mammogram and 
ultrasound. The mass was shown to be at 
least a borderline phyllodes tumor via 
sonographic percutaneous biopsy and 
confirmed malignant phyllodes tumor on 
final surgical excision.  
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Introduction 
In the United States, only 250-300 
cases of retinoblastoma are 
diagnosed each year.1  Patients with 
hereditary retinoblastoma, 
representing approximately 40% of 
patients, have germline mutations in 
the retinoblastoma gene, RB1, and 
frequently have bilateral or multifocal 
unilateral tumors.2 Due to 
improvements in diagnosis and 
treatment, patients with hereditary 
retinoblastoma are living into 
adulthood, and secondary 
malignancies are now the most 
common cause of death.3-7 Radiation 
therapy for hereditary retinoblastoma 
has been identified as a causative 
factor in the development of 
subsequent malignancies.3,5,7 The 
most common secondary 
malignancies reported include 
sarcoma, carcinoma, intracranial 
primitive neuroectodermal tumor, 
and melanoma.5 Breast, lung, and 
bladder carcinomas have been 
identified as the most frequent 
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secondary epithelial malignancies.6 
Phyllodes tumors of the breast are 
uncommon, representing less than 
1% of breast tumors.8 They usually 
occur in women 40-50 years of age 
and often present as palpable 
masses. Phyllodes tumors are 
commonly classified as benign, 
borderline or malignant, with 
approximately 10-20% of tumors 
classified as malignant.8 The 
average annual age-adjusted 
incidence rate of malignant phyllodes 
is 2.1 per 1 million women.9 The 
database of the National Cancer 
Institute's Surveillance, 
Epidemiology, and End Results 
(SEER) Program documented only 
158 patients with malignant 
phyllodes from 1973-1981.10 
Phyllodes tumors have been 
described with alterations in the 
expression of the retinoblastoma 
protein.11  
The occurrence of phyllodes tumor 
of the breast in the setting of 
retinoblastoma has only been 
reported in two patients.12 We report 
a case of malignant phyllodes tumor 
of the breast occurring in a patient 
with a history of hereditary 
retinoblastoma as an infant and 
leiomyosarcoma of the nasal cavity 
as a young adult. The imaging 
findings of phyllodes tumors and the 
association between these 
neoplasms are reviewed. 
 
 
 
Case Report 
The patient was diagnosed with 
hereditary bilateral retinoblastoma 
and treated with radiation therapy at 
four months of age. She then 
developed a leiomyosarcoma of the 
nasal cavity at age 29 (Figs. 1 & 2), 
which was diagnosed on excisional 
biopsy. She subsequently had a 
recurrence of the leiomyosarcoma 
treated with surgery at 30 years of 
age. The patient was never treated 
with chemotherapy and no radiation 
therapy was given for her nasal 
leiomyosarcoma before diagnosis of 
phyllodes. 
 
 
Figure 1. Axial facial CT image 
demonstrated a 3.4 cm soft tissue 
mass in the right nasal cavity 
(black arrow). 
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Figure 2. Microscopic examination 
of the right nasal mass excisional 
biopsy (hematoxylin and eosin 
stain; 400x magnification) 
showing atypical spindle cell 
neoplasm. 
At 32 years of age she presented 
with a new palpable right breast 
mass. A 1.6 cm irregular high density 
mass with microlobulated and ill-
defined margins (Figs. 3 and 4) in 
the subareolar region was 
demonstrated on digital 
mammography. Targeted right 
breast ultrasound of the subareolar 
region at the 11:30 position 
demonstrated a hypoechoic mass 
with microlobulated margins 
measuring 1.4 cm (Fig. 5), 
correlating with the mammographic 
abnormality. The differential 
diagnosis for the imaging findings 
included mammary carcinoma, 
fibroadenoma, and phyllodes tumor. 
A BIRADS 4 assessment was given 
and ultrasound-guided biopsy 
recommended. A second small 10 
mm oval circumscribed isodense 
mass was also noted on 
mammogram and ultrasound at the 
6:00 position. This mass was 
determined to be probably benign, a 
BIRADS 3 assessment given and a 6 
month follow-up mammogram was 
recommended. The patient’s 
physician preferred that both lesions 
be biopsied. 
 
 
Figure 3. Right CC (A) and MLO (B) views demonstrate a 1.6 cm irregular 
subareolar mass (white arrow). A second small 10 mm oval isodense mass 
was also noted at the 6:00 position (white arrow head). 
A B 
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Figure 4. Spot compression right CC (A) and MLO (B) views demonstrate 
persistence of the irregular subareolar mass with microlobulated and ill-
defined margins (white arrow). The second small 10 mm oval isodense 
mass also persists at the 6:00 position with circumscribed borders (white 
arrow head). 
                                                                          
 
 
Figure 5:  Longitudinal (A) and transverse (B) ultrasound images 
demonstrate a lobulated hypoechoic mass with microlobulated borders 
measuring 1.4 cm (white arrow). 
Ultrasound-guided core biopsy of 
both lesions was subsequently 
performed. Pathology of the smaller 
likely benign lesion at the 6:00 
position showed fibroadenoma. The 
core biopsy of the palpable mass 
demonstrated at least a borderline 
phyllodes tumor on histopathology, 
and surgical excision was 
recommended. The patient returned 
for surgical excision, with pathology 
demonstrating malignant phyllodes 
tumor (Fig. 6). Chromosomal 
analyses were not reported on any of 
her tumors. The patient initially 
underwent lumpectomy with close 
margin (1 mm from anterior inferior 
resection margin). Central breast 
excision was performed six weeks 
later and no residual tumor was 
identified.  At this time, there is no 
evidence of recurrence of the 
phyllodes. 
 
A B 
A B 
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Figure 6: Microscopic examination (hematoxylin and eosin stain) of the 
palpable breast mass at A) 20x magnification showing a fibroepithelial 
neoplasm with dilated epithelial lined clefts and B) at 400x magnification 
with stromal hypercellularity, atypia, and mitoses.   
Subsequently, the patient developed 
a second recurrence of the nasal 
leiomyosarcoma at the age of 33. 
She was treated surgically and is 
currently receiving external beam 
radiation therapy.   
Discussion 
Phyllodes tumors are uncommon 
breast tumors that frequently present 
as rapidly enlarging palpable 
masses. They average 3-6 cm in 
size at presentation, although tumor 
sizes from 1 cm to over 20 cm have 
been reported. Liberman et al. 
reported that tumors 3 cm or greater 
were significantly more likely to be 
malignant.13 Mammography typically 
demonstrates a large, round to oval, 
high density mass with 
circumscribed and lobulated 
margins. Sonography usually 
demonstrates a lobulated, well-
defined, heterogeneous, hypoechoic 
mass without posterior acoustic 
shadowing.14 There may be internal 
cystic spaces.13 Irregular shape has 
been significantly correlated with 
malignant and borderline phyllodes 
tumors.15 Color Doppler imaging 
frequently demonstrates some 
degree of internal vascularity. In our 
case, the malignant phyllodes 
showed irregular shape with 
microlobulated and ill-defined 
borders on mammography and 
hypoechoic mass with 
microlobulated borders on 
ultrasound, consistent with the 
reported imaging findings of 
malignant phyllodes tumors. On MRI, 
phyllodes tumors appear round or 
lobulated with smooth margins and 
often demonstrate heterogeneous 
signal intensity with cystic areas and 
nonenhancing septations. Signal 
intensity on T2 weighted imaging is 
variable and nearly always 
inhomogeneous. T1 signal intensity 
is usually iso- or hypointense to 
adjacent breast parenchyma.15 
Enhancement kinetics are variable.16 
Phyllodes tumors are treated with 
wide local excision. Margins of at 
least 1 cm are recommended. Local 
recurrence is reported to occur in 
A B 
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approximately 3-19% of patients.  
Sentinel lymph node biopsy or 
axillary dissection is not routinely 
performed, unless clinically 
indicated. There is no role for 
adjuvant chemotherapy, radiation 
therapy or hormonal therapy in the 
treatment of primary phyllodes 
tumor. Chemotherapy and radiation 
therapy may be considered on a 
case by case basis in the setting of 
recurrence or metastases. The 
survival rate of malignant phyllodes 
is much higher than nonphyllodes 
breast cancer. There is no data 
regarding differences in prognosis or 
management of malignant phyllodes 
in patients with or without 
retinoblastoma. 
Retinoblastoma occurs in both 
sporadic (somatic mutation) and 
familial (germinal mutation) forms.  
Knudson’s “two hit” hypothesis to 
explain retinoblastoma 
tumorigenesis requires two 
complementary chromosomal 
mutations.17 In the familial form of 
retinoblastoma, the ‘first hit” is a 
germline mutation followed by a 
somatic mutation of the remaining 
wild-type copy. These individuals are 
thus more susceptible to second 
non-ocular tumors because every 
cell in the body carries the germline 
mutation.   
The retinoblastoma susceptibility 
gene RB1, located on the long (q) 
arm of chromosome 13 at position 
14.2, functions as a tumor 
suppressor gene. The protein 
encoded by RB1, known as 
retinoblastoma protein or pRB, is 
vital to numerous cell processes, 
including DNA repair, cell cycle 
control, DNA replication, and 
proliferation.18 Cells with two altered 
copies of the RB1 gene produce no 
functional pRB and are unable to 
regulate cell division effectively. 
It is well known that hereditary 
retinoblastoma patients are 
susceptible to a wide variety of 
second malignancies, particularly 
soft tissue sarcomas in the setting of 
prior radiotherapy.3-7 Phyllodes 
tumors of the breast, however, are 
uncommonly reported as secondary 
tumors in these patients.12 Recent 
investigation has identified several 
chromosomal regions where 
amplifications, gains and losses 
were present in phyllodes tumors.19  
In particular, gains of 1q and losses 
of 13q are hallmark alterations in 
borderline and malignant phyllodes 
tumors.  Likewise, losses of 13q are 
identified in approximately 70% of 
leiomyosarcomas.20 Similar to 
phyllodes tumor, gains at 1q are 
identified in 50% of cases of 
retinoblastoma.21 The shared 
chromosomal alterations in these 
three tumor types suggest common 
genetic and cell signaling pathways 
that are altered and are in need of 
further study. Clinically, these 
patients are at high risk for 
developing a variety of malignancies 
in multiple sites, and thus close 
surveillance is necessary. 
Conclusion 
Retinoblastoma, malignant phyllodes 
tumor and nasal leiomyosarcoma are 
rare tumors. It is unlikely that these 
tumors would sporadically occur in 
the same patient. Recent 
chromosomal analysis suggests a 
Proceedings in Obstetrics and Gynecology, 2013; 3(2):5 
 
Malignant phyllodes with hereditary retinoblastoma 7 
 
possible common genetic etiology of 
phyllodes tumor and retinoblastoma, 
particularly 1q gains and 13q losses 
with RB1 alterations. Further 
evaluation of the role of RB1 
alterations in the oncogenesis of 
phyllodes tumor is warranted. 
Furthermore, the differential 
diagnosis of a breast mass in a 
patient with a history of 
retinoblastoma should include 
phyllodes tumor. 
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